Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway. Our business model is to develop proprietary innovations to FDA-approved, injectable drugs, which we refer to as branded listed drugs, that offer longer commercial duration provided by orphan drug exclusivity, new intellectual property protection, and/or three years of non-patent regulatory exclusivity as provided under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch Waxman Act.